Up next

Autoplay

Secukinumab [THU0325] ( Part 1) - Psoriatic Arthritis Posters and Abstracts from Amsterdam

2 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

Visit https://annenberg.net/Psoriati....c-Arthritis-EULAR-CM for the complete CE/CME activity and to claim credit.

This is module (1 of 5) of the CE/CME activity Psoriatic Arthritis Posters and Abstracts from Amsterdam which covers key posters presented at the Annual European Congress of Rheumatology EULAR 2018 meeting in Amsterdam, June 13-16, 2018.

This module covers:
[THU0325] Secukinumab Demonstrates a Consistent Safety Profile With Up to Five Years Treatment in Patients With Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

Show more
0 Comments sort Sort By

Up next

Autoplay